Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: Interaction between opioid and cannabinoid systems

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT2, 2008, Pages

  Shafaroodi, Hamed ^a   Ghasemi, Mehdi ^b   Dehpour, Ahmad R ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cannabinoids; Cholestasis; Clonic seizure threshold; Mice; Opioids

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; NALTREXONE; OPIATE RECEPTOR; PENTETRAZOLE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CHRONIC DRUG ADMINISTRATION; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE THRESHOLD; SHAM PROCEDURE;

EID: 47649110284     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05101.x     Document Type: Article

References (63)

1. Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. J. Gastroenterol. Hepatol. 2002 17 : 938 48.
2. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br. Med. J. 1988 297 : 1501 4.
3. Bergasa NV, Alling DW, Talbot TL et al. Effects of naloxone-reversible antinociception. Ann. Intern. Med. 1995 123 : 161 7.
4. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992 103 : 630 5.
5. Ghafourifar P, Dehpour AR, Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor, of naloxone-precipitated withdrawal signs in a mouse model cholestasis. Life Sci. 1997 60 : 265 70.
6. Dehpour AR, Meysami F, Ebrahimi-Daryani N, Akbarloo N. Inhibition by lithium of opioid withdrawal-like syndrome and physical dependency in a model of acute cholestasis in mice. Hum. Psychopharmacol. Clin. Exp. 1998 13 : 407 12.
7. Bergasa NV, Talbot TL, Schmitt JP et al. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998 27 : 679 84.
8. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down-regulated in rat model of cholestasis. J. Hepatol. 1992 15 : 220 4.
9. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu opioid receptors are down-regulated in a rat model of cholestasis. J. Hepatol. 1992 15 : 220 4.
10. Bergasa NV, Alling DW, Vergalla J, Xu H, Swain MG, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J. Hepatol. 1994 20 : 85 90.
11. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol. Ther. 2002 95 : 103 17.
12. Pertwee RG. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. In : Pertwee RG, ed. Cannabinoid Receptors. London, San Diego, CA : Academic Press, 1995 69 83.
13. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 1998 5 : 534 51.
14. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet restricted mice. Eur. J. Pharmacol. 2000 392 : 147 56.
15. Ashton CH. Adverse effects of cannabis and cannabinoids. Br. J. Anaesth. 1999 83 : 637 49.
16. Gabbay E, Avraham Y, Ilan Y, Israeli E, Berry EM. Endocannabinoids and liver disease-review. Liver Int. 2005 25 : 921 6.
17. Fernández-Rodrigez CM, Romero J, Petros TJ et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 2004 24 : 477 83.
18. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta(9)-tetrahydrocannabinol-induced apoptisis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 2002 302 : 451 65.
19. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee S. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br. J. Pharmacol. 2005 146 : 315 23.
20. Neff GW, O'Brien CB, Reddy KR et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am. J. Gastroenterol. 2002 97 : 2117 19.
21. Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55 2 12-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci. 2003 73 : 2741 7.
22. Frenk H, McCarthy B, Liebskind J. Different brain areas mediate the analgesic and epileptic properties of enkephalin. Science 1978 200 : 335 7.
23. Urca G, Frenk H, Liebskind J, Taylor A. Morphine and enkephalin: analgesic and epileptic properties. Science 1977 197 : 83 8.
24. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res. 1983 287 : 197 210.
25. Ramabadran K, Bansinath M. Endogenous opioid peptides and epilepsy. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990 28 : 47 62.
26. Przewlocka B, Stala L, Lason W, Przewlocki R. The effects of various opiate receptor agonists on the seizure threshold in the rat, is dynorphin an endogenous anticonvulsant? Life Sci. 1983 33 (Suppl. 1 595 8.
27. Homayoun H, Khavandgar S, Namiranian Kh, Gaskari SA, Dehpour AR. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res. 2002 48 : 33 41.
28. Tortella F, Robles L, Holaday J, Cowan A. A Selective role for δ-receptors in the regulation of opioid-induced changes in seizure thresholds. Life Sci. 1983 33 : 603 6.
29. Chesher GB, Jackson DM. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 1974 37 : 255 64.
30. Turkanis SA, Chiu P, Borys HK, Karler R. Influence of delta9-tetrahydrocannabinol and cannabidiol on photically evoked after-discharge potentials. Psychopharmacology (Berl.) 1977 52 : 207 12.
31. Karler R, Murphy V, Calder LD, Turkanis SA. Pentylenetetrazol kindling in mice. Neuropharmacology 1989 28 : 775 80.
32. Usami N, Kobana K, Yoshida H et al. Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. Chem. Pharm. Bull. (Tokyo) 1998 46 : 1462 7.
33. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 2001 428 : 51 7.
34. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 2002 452 : 295 301.
35. Shafaroodi H, Samini M, Moezi L et al. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004 47 : 390 400.
36. Homayoun H, Sayyah M, Dehpour AR. The additive effect of opioids and nitric oxide in increasing pentylenetetrazole-induced seizure threshold in cholestatic mice. J. Gastroenterol. Hepatol. 2002 17 : 96 101.
37. Dehpour AR, Rastegar S, Jorjani M, Roushanzamir F, Joharchi KH, Ahmadiani A. Subsensitivity to opioids is receptor specific in isolated guinea pig ileum and mouse vas deferens after obstructive cholestasis. J. Pharmacol. Exp. Ther. 2000 293 : 946 51.
38. Pourpholami MH, Majzoob S, Javadi M, Kamalinejad M, Fanaee GHR, Sayyah M. The fruit essential oil of pimpinella anisum exerts anticonvulsant effects in mice. J. Ethopharmacol. 1999 66 : 211 15.
39. Thomas DA, Williams GW, Iwata K, Kenshalo DR Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res. 1992 585 : 315 17.
40. Mombeini T, Roushanzamir F, Jorjani M et al. Alteration in specific opioid-receptor labeling on peripheral blood leukocytes of bile duct-ligated rat. Pathophysiology 2006 13 : 111 17.
41. Kiani S, Ebrahimkhani MR, Shariftabrizi A et al. Opioid system blockade decreases collagenase activity and improves liver injury in a rat model of cholestasis. J. Gastroenterol. Hepatol. 2006 22 : 406 13.
42. Bohme G, Stutzmann JM, Roques B, Blanchard JC. Effects of selective μ- and δ-opioid peptides on kindled amygdaloid seizures in rats. Neurosci. Lett. 1987 74 : 227 31.
43. Tortella FC, Cowan A. Studies on opioid peptides as endogenous anticonvulsants. Life Sci. 1982 31 : 2225 9.
44. Tortella FC, Long JB, Holaday JW. Endogenous opioid systems. Physiological role in the self-limitation of seizures. Brain Res. 1985 332 : 174 8.
45. Batkai S, Jarai Z, Wagner JA et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 2001 7 : 827 32.
46. Ros J, Claria J, To-Figueras J et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002 122 : 85 93.
47. Navarro M, Carrera MRA, Fratta W et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 2001 21 : 5344 50.
48. Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol. 2001 63 : 569 611.
49. Paquette J, Olmstead M. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception. Behav. Pharmacol. 2005 16 : 597 603.
50. Maldonado R, Rodríguez de Fonseca F. Cannabinoid addiction: behavioural models and neuronal correlates. J. Neurosci. 2002 22 : 3326 31.
51. Christie MJ. Opioid and cannabinoid receptors: friends with benefits or just close friends? Br. J. Pharmacol. 2006 148 : 385 6.
52. Ledent C, Valverde O, Cossu G et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999 283 : 401 4.
53. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitisation to locomotor responses in CB1 knockout mice. Eur. J. Neurosci. 2000 12 : 4038 46.
54. Ghozland S, Matthes HWD, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci. 2002 22 : 1146 54.
55. Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. 2004 16 : 159 72.
56. Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol. Biochem. Behav. 2005 81 : 360 8.
57. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 1999 20 : 287 94.
58. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997 276 : 2048 50.
59. Berrendero F, Mendizabal V, Murtra P, Kieffer BL, Maldonado R. Cannabinoid receptor and WIN 55 2 12-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur. J. Neurosci. 2003 18 : 2197 202.
60. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci. 2001 13 : 1816 24.
61. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 1999 848 : 183 90.
62. Pugh GJ, Mason DJJ, Combs V, Welch SP. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55 9 40 in the spinal cord. J. Pharmacol. Exp. Ther. 1997 281 : 730 7.
63. Jardinaud F, Crété D, Canestrelli C, Ledent C, Roquesa BP, Noble F. CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited. Brain Res. 2005 1063 : 77 83.